Related Articles
Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib
The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR‑TKIs but is not an indication of acquired resistance to EGFR‑TKIs in NSCLC patients with EGFR mutations
Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation‑positive non‑small cell lung cancer, receiving treatment with gefitinib or erlotinib
Cut-off levels of NSE to differentiate SCLC from NSCLC
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations